HAVCR2 and non-small cell lung carcinoma: TIM-3, known for its presence on CTL, NK, Treg, DC, and macrophages (where it promotes M2 polarization), is a critical immune checkpoint being investigated in various clinical trials for solid tumors, including NSCLC (182).